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Power calculations to determine the sample size were not performed. All eligible patients referred to the endoscopy unit of the study hospital were invited to participate. Eighty patients were included in the study and were divided into two groups of 40 patients each. Two patients in each group were excluded after randomisation, because of adverse effects, failing to attend study appointments, allergy episode, and being prescribed a longer eradication therapy. The final study groups included 38 patients in each group. The mean age of the patients in the intervention group was 49.3 (+/-16.3) years, and 73.7% were men. The mean age of the patients in the control group was 50.7 (+/-15.7) years, and 68.4% were men.
Study design
This was a prospective, randomised controlled study that was carried out in a single centre, the Antrim Area Hospital. Randomisation was performed using a sealed envelope technique. The patients were followed for 6 months. A urea breath test was conducted 4 to 6 weeks after the one-week therapy to assess the actual eradication. In addition, 10 days after the endoscopy, all patients were contacted by telephone to evaluate the potential side effects experienced during the eradication therapy. The loss to follow-up was 4 patients (two in each group).
Analysis of effectiveness
The analysis of the clinical study appears to have been conducted on the basis of treatment completers only. The primary health outcome was the eradication rate, which was defined as the absence of H. pylori after a urea breath test. The secondary health outcomes were:
adverse drug effects such as nausea, vomiting, diarrhoea, taste disturbance, abdominal pain, headache, itching or rash; compliance, assessed indirectly through patient interviews by telephone and by pill counts after completion of the eradication therapy; and patient response to the therapy, measured on the basis of dyspeptic symptoms in eradicated versus persistent patients and the use of antisecretory medications. The presence and severity of dyspeptic symptoms were assessed using a modified version of the Gastrointestinal Symptom Rating Scale, patient interviews on the day of endoscopy and one month and 6 months after completion of the therapy, and consultations with general practitioners (GPs) for the treatment of dyspeptic symptoms.
The study groups were shown to be comparable in terms of age, gender, social habits such as smoking and alcohol intake, and the duration of dyspeptic symptoms prior to eradication therapy.
Effectiveness results
The eradication rate was 94.7% in the intervention group and 73.7% in the control group, (95% confidence interval of difference, 95% CI: 5.3% -36.7%; p=0.027).
The overall eradication rate for the whole sample of 76 patients was 84.2% (64 eradicated and 12 persistent).
The number of patients experiencing adverse events was 19 (50%) in the intervention group and 17 (44.7%) in the control group, (p=0.81).
The compliance rate was 100% in 35 patients (91.2%) in the intervention group and in 9 patients (23.7%) in the control group (95% CI for the difference: 52.3% -84.5%; p<0.001).
All H. pylori persistent patients took less than 60% of the prescribed regimen, while all eradicated patients took at least 65% of the prescribed medication.
In terms of the assessment of dyspeptic symptoms, the severity scores for individual dyspeptic symptoms were much lower for patients successfully eradicated than for persistent patients. Most of these differences reached statistical significance at both the one-month and 6-month follow-up assessments.
